Skip Navigation.

Site Map.

Help.

Account.

Cart.

Home

This Web site is a component of the SAMHSA Health Information Network.

Quick Find & Order

Top 50

Pubs in Series

Posters

Videos

Spanish

Drugs

Audiences

Issues

Publications Home

NCADI Home

This Web site is a component of the SAMHSA Health Information Network.

Naltrexone And Alcoholism Treatment
Treatment Improvement Protocol (TIP) Series 28

Appendix A -- Bibliography

Addiction Research Foundation (ARF).: Fast Fax Facts on Naltrexone. Toronto, Ontario, Canada: Addiction Research Foundation, January 1996.

Alcoholics Anonymous, 3rd ed.: New York: Alcoholics Anonymous World Services, Inc., 1976.

Allan, A.M., and Harris, R.A.: Acute and chronic ethanol treatments alter GABA receptor-operated chloride channels. Pharmacology, Biochemistry and Behavior 27:665-670, 1987.; Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised (DSM-III-R), Washington, DC : American Psychiatric Association, 1987.

American Society of Addiction Medicine.: Patient Placement Criteria for the Treatment of Substance-Related Disorder, 2nd ed. Chevy Chase, MD: American Society of Addiction Medicine, 1996.

Annis, H.M., and ~~Peachy~~ Peachey, J.E.: The use of calcium carbimide in relapse prevention ~~counseling~~ counselling: Results of a randomized controlled trial. British Journal of Addiction 87:63-72, 1992.

Anton, R.F.: New directions in the pharmacotherapy of alcoholism. Psychiatric Annals 25:353-362, 1995.

Anton, R.F.: Naltrexone as Adjunctive Treatment to Cognitive Behavioral Therapy for Outpatient Alcoholics. Paper presented at the annual meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 1997.

Anton, R.F.; Moak, D.H.; and Latham, P.K.: The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry 53(3):225-231, 1996.

Atkinson, R.L.: Endocrine and metabolic effects of opiate antagonists. Journal of Clinical Psychiatry 45(9):20B24, 1984.

Bien, T.; Miller, W.; and Tonigan, J.: Brief interventions for alcohol problems: A review. Addiction 88(3):315-335, 1993.

Bohn, M.J.; Krahn, D.D.; and Staehler, B.A.: Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clinical and Experimental Research 19(3):600-606, 1995.

Bohn, M.J.; Kranzler, H.R.; Beazoglou, D.; and Staehler, B.A.: Naltrexone and brief counseling to reduce heavy drinking. American Journal of the Addictions 3:91-99, 1994.

Bray, J.H., and Rogers, J.C.: Linking psychologists and family physicians for collaborative practice. Professional Psychology: Research and Practice 26:132-138,1995.

Carroll, K.; Ziedonis, D.; O'Malley, S.S.; McCance-Katz, E.; Gordon, L.; and Rounsaville, B.: Pharmacologic interventions for alcohol- and cocaine-abusing individuals: A controlled study of disulfiram vs. naltrexone. American Journal on Addictions 2:77-79, 1993.

Center for Substance Abuse Treatment (CSAT).: Detoxification from Alcohol and Other Drugs. Treatment Improvement Protocol (TIP) Series, Number 19. DHHS Publication No. (SMA) 95-3046. Washington, DC: U.S. Government Printing Office, 1995.

Center for Substance Abuse Treatment (CSAT).: Substance Abuse Treatment and Domestic Violence. Treatment Improvement Protocol (TIP) Series, Number 25. DHHS Publication No. (SMA) 97-3163. Washington, DC: U.S. Government Printing Office, 1997.

Charness, M.E.: Alcohol and the brain. Alcohol Health and Research World 14(2):85-89, 1990.

Charness, M.E.; Hu, G.; Edwards, R.H.; and Querimit, L.A.: Ethanol increases delta-opioid receptor gene expression in neuronal cell lines. Molecular Pharmacology 44:1119-1127, 1993.

Charness, M.E.; Querimit, L.A.; and Diamond, I.: Ethanol increases the expression of functional delta-opioid receptors in the neuroblastoma X glioma NG108-15 hybrid cells. Journal of Biologic Chemistry 261:3164-3169, 1986.

Cloninger, C.R.: Recent advances in family studies of alcoholism. Progress in Clinical and Biological Research 241:47-60, 1987.

Cloninger, C.R.: Etiologic factors in substance abuse: An adoption study perspective. In: Pickens, R.W., and Svikis, D.S., eds. Biological Vulnerability to Drug Abuse. NIDA Research Monograph Series, Number 89. Rockville, MD: National Institute on Drug Abuse, 1988. pp. 52-72.

Cornelius, J.R.; Salloum, I.M.; Ehler, J.G.; Jarrett, P.J.; Cornelius, M.D.; Perel, J.M.; Thase, M.E.; and Black, A.: Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Archives of General Psychiatry 54:700-705, 1997.

Croop, R.S., and Chick, J.: American and European clinical trials of naltrexone. In: Litten, R.Z., and Fertig, J. (chairs), International Update: New Findings on Promising Medications. Alcoholism: Clinical and Experimental Research 20(8 suppl.):216A-218A, 1996.

Croop, R.S.; Faulkner, E.B.; and Labriola, D.F., for the Naltrexone Usage Study Group.: The safety profile of naltrexone in the treatment of alcoholism: Results from a multicenter usage study. Archives of General Psychiatry 54(12):1130-1135, 1997.

Croop, R.S.; Labriola, D.F.; Wroblewski, J.M.; and Nibbelink, D.W.: A Multicenter Safety Study of Naltrexone as Adjunctive Pharmacotherapy for Individuals with Alcoholism. Paper presented at the American Psychiatric Association's 148th annual meeting in Miami, May 20-25, 1995.

Davidson, D.; Swift, R.; and Fitz, E.: Naltrexone increases the latency to drink alcohol in social drinkers. Alcoholism: Clinical and Experimental Research 20:732-739, 1996.

deWaele, J.P.; Papachristou, D.N.; and Gianoulakis, C.: The alcohol-preferring C57-L/6 mice present an enhanced sensitivity of the hypothalmic b-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. Journal of Pharmacology and Experimental Therapeutics 281:788-794, 1992.

Di Chiara, G.: Alcohol and dopamine. Alcohol Health and Research World 21(2):108-114, 1997.

Dillon, D., and Homer, A.L.: Answers to frequently asked questions about naltrexone treatment for alcoholism. In: Rounsaville, B.J.; O'Malley, S.; and O'Conner, P., eds. Guidelines for the Use of Naltrexone in the Treatment of Alcoholism. New Haven, CT: APT Foundation, 1995.

Doty, P., and deWit, H.: Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behavioral Pharmacology 6:386-394, 1995.

Doyle, R.: Deaths ~~due to~~ caused by alcohol. Scientific American, Dec. 1996.

DuPont Pharma.: Product Monograph: ReVia (naltrexone HCl). 1995.

Farren, C.K., and O'Malley, S.: Sequential use of naltrexone in the treatment of relapsing alcoholism. American Journal of Psychiatry154(5):714, 1997.

Fleming, M.F., and Barry, K.L.: Clinical overview of alcohol and drug disorders. In: Fleming, M.F., and Barry, K.L., eds. Addictive Disorders. Chicago: Mosby Yearbook, 1992. pp. 3-21.

Froehlich, J.C.: Genetic factors in alcohol self-administration. Journal of Clinical Psychiatry 56(suppl. 7):15-23, 1995.

Froehlich, J.C.: The neurobiology of ethanol-opioid interactions in ethanol reinforcement. Alcoholism: Clinical and Experimental Research 20:181A-186A, 1996.

Froehlich, J.C.: Opioid peptides. Alcohol Health and Research World 21(2):132-135, 1997.

Froehlich, J.C., and Li, T.-K.: Opioid peptides. In: Galanter, M., ed. Recent Developments in Alcoholism: Volume 11. Ten Years of Progress. New York: Plenum Press, 1993. pp. 187-205.

~~Froehlich, J.C., and Wand, G.~~: ~~The neurobiology of ethanol-opioid interactions in ethanol reinforcement.~~ ~~Alcoholism: Clinical and Experimental Research~~ ~~20(8)181A-186A,~~ ~~1996.~~

Frye, G.D., and Breese, G.R.: GABAergic modulation of ethanol-induced motor impairment. Journal of Pharmacology and Experimental Therapeutics 223:750-756, 1982.

Gamage, J.R., and Zerkin, E.L.: Narcotic Antagonists. National Clearinghouse for Drug Abuse Information Report Series 26, No. 1, October 1973.

Gianoulakis, C., and Angelogianni, P.: Characterization of beta-endorphin peptides in the spinal cord of the rat. Peptides 10(5):1049-1054, 1989.

Gianoulakis, C.; Angelogianni, P.; Meany, M.; Thavundayil, J.; and Thawar, V.: Endorphins in individuals with high and low risk for development of alcoholism. In: Reid, L.D., ed. Opioids, Bulimia, and Alcohol Abuse and Alcoholism. New York: Springer-Verlag, 1990. pp. 229-246.

Gianoulakis, C., and Barcomb, A.: Effect of acute ethanol in vivo and in vitro on the beta-endorphin system in the rat. Life Sciences 40(1):19B28, 1987.

Gianoulakis, C.; Krishnan, B.; and Thavundayil, J.: Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Archives of General Psychiatry 53:250-257, 1996.

Ginsburg, H.M.: Naltrexone: Its Clinical Utility. Treatment Research Report, DHHS Publication No. (ADM) 84-1358. Bethesda, MD: National Institute on Drug Abuse, 1984.

Goodwin, D.W.; Schulsinger, F.; Hermansen, L.; Guze, S.D.; and Winokur, G.: Alcohol problems in adoptees raised apart from alcoholic biological parents. Archives of General Psychiatry 28:238-243, 1973.

Gonzales, R.A., and Jaworski, J.N.: Alcohol and glutamate. Alcohol Health and Research World 21(2):120-126, 1997.

Gonzalez, J.P., and Brogden, R.N.: Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192-213, 1988.

Gonzalez, N.M.; Campbell, M.; Small, A.M.; Shay, J.; Bluhm, L.D.; Adams, P.B.; and Foltz, R.L.: Luteinizing hormone regulators: Luteinizing hormone releasing hormone analogs, estrogens, opiates, and estrogen-opiate hybrids. Psychopharmacology Bulletin 30(2):203-208, 1994.

Grant, B.F.: DSM-II-R and proposed DSM-IV alcohol abuse and dependence, United States, 1988: A nosological comparison. Alcoholism: Clinical and Experimental Research 16(6):1068-1077, 1992.

Gritz, E.R.; Shiffman, S.M.; Jarvik, M.E.; Schlesinger, J.; and Charuvastra, V.C.: Naltrexone: Physiological and psychological effects of single doses. Clinical Pharmacology and Therapeutics 19:773-776, 1976.

Hiller-Sturmhöfel, S.: Signal transmission among nerve cells. Alcohol Health and Research World 19(2):128, 1995.

Ho, A.K.S.; Chen, R.C.A.; ~~and Morrison, J.M.~~: Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states. Annals of the New York Academy of Sciences 281:297-310, 1976.

Institute for Health Policy, Brandeis University.: Substance Abuse: The Nation's Number One Health Problem: Key Indicators for Policy. Princeton, NJ: The Robert Wood Johnson Foundation, 1993.

Institute of Medicine.: Broadening the Base of Treatment for Alcohol Problems. Washington, DC: National Academy Press, 1996.

Jaffe, J.H.: Cyclazocine in the treatment of narcotic addiction. Current Psychiatric Therapies 7:147-156, 1967.

Jaffe, A.J.; Rounsaville, B.; Chang, G.; Schottenfeld, R.S.; Meyer, R.E.; and O'Malley, S.S.: Naltrexone, relapse prevention, and supportive therapy with alcoholics: An analysis of patient treatment matching. Journal of Consulting and Clinical Psychology 64:1044-1053, 1996.

Jenab, S., and Inturrisi, C.E.: Ethanol and naloxone differentially upregulate delta opioid receptor gene expression in neuroblastoma hybrid (NG108-15) cells. Molecular Brain Research 27:95-102, 1994.

Judson, B.A.; Carney, T.M.; and Goldstein, A.: Naltrexone treatment of heroin addiction: Efficacy and safety in a double-blind dosage comparison. Drug and Alcohol Dependence 7:325-346, 1981.

Julius, D., and Renault, P., eds.: Narcotic Antagonists: Naltrexone Progress Report. NIDA Research Monograph Series, Number 9. DHEW Publication No. (ADM) 76-387. Bethesda, MD: National Institute on Drug Abuse, 1976.

Keith, L.D.; Crabbe, J.C.; Robertson, L.M.; and Kendall, J.W.: Ethanol stimulated endorphin and corticotropin in vitro. Brain Research 367(1-2):222-229, 1986.

King, A.C.; Volpicelli, J.R.; Frazer, A.; and O'Brien, C.P.: Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15-22, 1997.

Koob, G.F., and LeMoal, M.: Drug abuse: Hedonic homeostatic dysregulation. Science 278(5335):52-58, 1997.

Koob, G.F.; Rassnick, S.; Heinrichs, S.; and Weiss, F.: Alcohol: The reward system and dependence. In: Jansson, B.; Jörnvall, H.; Rydberg, U.; Terenius, L.; and Vallee, B.L., eds. Toward a Molecular Basis of Alcohol Use and Abuse, Boston: Birkhauser-Verlag, 1994. pp. 103-114.

Kranzler, H.R.; Burleson, J.A.; Korner, P.; Del Boca, F.K.; Bohn, M.J.; Brown, J.; and Liebowitz, N.: Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 152:391-397, 1995.

Kranzler, H.R., and Meyer, R.E.: An open trial of buspirone in alcoholics. Journal of Clinical Psychopharmacology 9(5):379-380, 1989.

Kranzler, H.R.; Tennen, H.; Penta, C.; and Bohn, M.J.: Targeted naltrexone treatment of early problem drinkers. Addictive Behavior 22(3):431-436, 1997.

Kuhar, M.J.: Basic Neurobiological Research: 1989-1991. Drug Abuse and Drug Abuse Research: Fourth Triennial Report to Congress from the Secretary, Department of Health and Human Services. Rockville, MD: National Institute on Drug Abuse, 1991 (unpublished document).

Le, A.D., and Sellers, E.M.: Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake. Alcohol and Alcoholism 29(suppl. 2):545-549, 1994.

LeMarquand, D.; Pihl, R.O.; and Benkelfat, C.: Serotonin and alcohol intake, abuse, and dependence: Clinical evidence. Biological Psychiatry 36(5):326-337, 1994.

Leshner, A.I.: Addiction is a brain disease, and it matters. Science 278(5335):45-47, 1997.

Li, X.-W.; Li, T.-K.; and Froehlich, J.C.: Alcohol alters preproenkephal in mRNA content in the shell and the core of the nucleus accumbens. Alcoholism: Clinical and Experimental Research 20:53A, 1996.

~~Liljequest,~~ Liljequist S., and Engel, J.: Effects of GABAergic agonists and antagonists on various ethanol-induced behavioral changes. Psychopharmacology 78:71-75, 1982.

Litten, R.Z.; Allen, J.; and Fertig, J.: Pharmacotherapies for alcohol problems: A review of research with focus on developments since 1991. Alcoholism: Clinical and Experimental Research 20:859-876, 1996.

Little, H.J.: Mechanisms that may underlie the behavioral effects of ethanol. Progress in Neurobiology 36:171-194, 1991.

Lozano Polo, J.L.; Gutierrez Mora, E.; Martinez Perez, V.; Santamaria Gutierrez, J.; Vada Sanchez, J.; and Vallejo Correas, J.A.: [Effect of methadone or naltrexone on the course of transaminase[s] in parenteral drug users with hepatitis C virus infection.] Revista Clinica Espanola 197(7):479-483, 1997.

Malec, T.S.; Malec, E.A.; and Doniger, M.: Efficacy of buspirone in alcohol dependence: A review. Alcoholism: Clinical and Experimental Research 20(5):853-858, 1996.

Mason, B.J.: Dosing issues in the pharmacotherapy of alcoholism. Alcohol: Clinical and Experimental Research 20(suppl. 7):10A-16A, 1996.

Mason, B.J.; Kocsis, J.H.; Ritvo, E.C.; and Cutler, R.B.: A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association 275:761-767, 1996.

Mason, B.J.; Ritvo, E.C.; Morgan, R.O.; Salvato, F.R.; Goldberg, G.; Welch, B.; and Mantero-Atienza, E.: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol: Clinical and Experimental Research 18(5):1162-1167, 1994.

Maxwell, S., and Shinderman, M.: Naltrexone in the Treatment of Alcohol-Dependent, Mentally Ill Patients: A Retrospective Analysis of 83 Cases. Paper presented at the annual meeting of the American Society of Addiction Medicine, San Diego, California, April 1997.

McBride, W.J.; Murphy, J.M.; Yoshimoto, K.; Lumeng, L.; and Li, T.-K.: Serotonin mechanisms in alcohol drinking behavior. Drug Development Research 30:170-177, 1993.

McCaul, M.E.: Efficacy of naltrexone for alcoholics with and without comorbid opiate or cocaine dependence. In: Litten, R.Z., and Fertig, J., Chairs. International Update: New Findings on Promising Medications. Alcoholism: Clinical and Experimental Research 20(suppl.):216A-218A, 1996.

McGrath, P.J.; Nunes, E.V.; Stewart, J.W.; Goldman, D.; Agosti, V.; Ocepek-Welikson, K.; and Quitkin, F.M.: Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Archives of General Psychiatry 53(3):232-240, 1996.

Mello, N.K.; Mendelson, J.H.; Kuehnle, J.C.; and Sellers, M.S.: Operant analysis of human heroin self-administration and the effects of naltrexone. Journal of Pharmacology and Experimental Therapeutics 216:45-54, 1981.

Mihic, S.J., and Harris, R.A.: GABA and the GABA_A receptor. Alcohol Health and Research World 21(2):127-131, 1997.

Miller, W.R., and Hester, R.K.: Inpatient alcoholism treatment: Who benefits? American Psychologist 41(7):794-805, 1986.

Naranjo, C.A.; Kadlec, K.E.; Sanhueza, P.; Woodley-Remus, D.; and Sellers, E.M.: Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology and Therapeutics 47:490-498, 1990.

Naranjo, C.A.; Sellers, E.M.; Roach, C.A.; Woodley, D.V.; Sanchez-Craig, M.; and Sykora, K.: Zimelidine-induced variations in alcohol intake in non-depressed heavy drinkers. Clinical Pharmacology and Therapeutics 35:374-381, 1984.

Naranjo, C.A.; Sellers, E.M.; Sullivan, J.T.; Woodley, D.V.; Kadlec, K.; and Sykora, K.: The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clinical Pharmacology and Therapeutics 41:266-274, 1987.

Naranjo, C.A.; Sullivan, J.T.; Kadlec, K.E.; Woodley-Remus, D.V.; Kennedy, G.; and Sellers, E.M.: Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clinical Pharmacology and Therapeutics 46:301-309, 1989.

Nash, J.M.: Addicted. Time 149(18):69-76, 1997.

National Institute on Alcohol Abuse and Alcoholism (NIAAA).: Eighth Special Report to the U.S. Congress on Alcohol and Health From the Secretary of Health and Human Services, September 1993. NIH Pub. No. 94-3699. Bethesda, MD: National Institutes of Health, 1994.

National Institute on Alcohol Abuse and Alcoholism (NIAAA).: Neuroscience research and medications development. Alcohol Alert No. 33 (PH 366), July 1996.

O'Brien, C.P.; Volpicelli, L.A.; and Volpicelli, J.R.: Naltrexone in the treatment of alcoholism: A clinical review. Alcohol 13(1):35-39, 1996.

O'Connor, P.G.; Farren, C.K.; Rounsaville, B.J.; and O'Malley, S.S.: A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers. American Journal of Medicine 103(6):477B482, 1997.; Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association 279(3):229B234, 1998.

O'Malley, S.S.; Croop, R.S.; Wroblewski, J.M.; Labriola, D.F.; and Volpicelli, J.R.: Naltrexone in the treatment of alcohol dependence: A combined analysis of two trials. Psychiatric Annals 25:681-688, 1995.

O'Malley, S.S.; Jaffe, A.J.; Chang, G.; Rode, S.; Schottenfeld, R.S.; Meyer, R.E.; and Rounsaville, B.: Six month follow-up of naltrexone and psychotherapy for alcohol dependence. Archives of General Psychiatry 53:217-224, 1996a.

O'Malley, S.S.; Jaffe, A.J.; Chang, G.; Schottenfeld, R.S.; Meyer, R.E.; and Rounsaville, B.: Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 49:881-887, 1992.

O'Malley, S.S.; Jaffe, A.J.; Rode, S.; and Rounsaville, B.J.: Experience of a "slip" among alcoholics treated with naltrexone or placebo. American Journal of Psychiatry 153: 281-283, 1996b.

O'Malley, S.S.; Krishnan-Sarin, S.; Farren, C.K.; O'Connor, P.G.; Golubchikov, V.; and Rounsaville, B.J.: Predictors of naltrexone-induced nausea in alcohol-dependent subjects. Alcoholism: Clinical and Experimental Research 20:91A, 1996c.

Oslin, D.; Liberto, J.; O'Brien, C.P.; Krois, S.; and Norbeck, J.: Naltrexone as an adjunctive treatment for older patients with alcohol dependence. American Journal of Geriatric Psychiatry 5:324-332, 1997.

Pettinati, H.M.: Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 20(7):23A-29A, 1996.

Physicians Desk Reference (PDR), 51st ed.: Montvale, NJ: Medical Economics, 1997.

Pickens, R.W.; Svikis, D.S.; McGue, M.; Lykken, D.T.; Heston, L.L.; and Clayton, P.J.: Heterogeneity in the inheritance of alcoholism. Archives of General Psychiatry 48:19-28, 1991.

Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.I.; Judd, L.L.; and Goodwin, F.K.: Comorbidity of mental disorders with alcohol and other drug use: Results from the epidemiologic catchment area (ECA) study. Journal of the American Medical Association 264:2511-2518, 1990.

Reid, L.D.; Delconte, J.D.; Nichols, M.L.; Bailey, E.J.; and Hubbard, C.J.: Tests of opioid deficiency ~~hypothesis~~ hypotheses of alcoholism. Alcohol 8:247-257, 1991.

Reid, L.D.; ~~Gardel,~~ Gardell, L.R.; Chattopadyay, S.; and Hubbell, C.L.: Periodic naltrexone and propensity to take alcoholic beverage. Alcohol Clinical and Experimental Research 20:1329-1334, 1996.

Research Institute on Addictions.: New drug approved for alcoholism treatment: RIA study plays role in approval. Research in Brief May 1995.

Restak, R.R.: The Mind. New York: Bantam Books, 1988.

Rice, D.P.; Kelma, S.; Miller, L.S.; and Dunmeyer, S.: The Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1985. DHHS Publication No. (ADM) 90-1694. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1990.

Salloum, I.M.; Cornelius, J.R.; Thase, M.E.; Daley, D.C.; Kirisci, L.; and Spotts, C.: Naltrexone utility in depressed alcoholics. Psychopharmacology Bulletin 34(1):111-115, 1998.

Sax, D.S.; Kornetsky, C.; and Kim, A.: Lack of hepatotoxicity with naltrexone treatment. Journal of Clinical Pharmacology 34(9):898-901, 1994.

Schurman, R.A.; Kramer, P.D.; and Mitchell, J.B.: The hidden mental health network: Treatment of mental illness by nonpsychiatric physicians. Archives of General Psychiatry 42:89-94, 1985.

Shapiro, S.; Skinner, E.A.; Kessler, L.G.: Utilization of health and mental health services: Three epidemiological catchment area sites. Archives of General Psychiatry 41:971-978, 1984.

Siegel, S.: Alcohol and opiate dependence: Reevaluation of the Victorian perspective. In: Cappell, H.D.; Glaser, F.B.; and Israel, Y., et al., eds. Research Advances in Alcohol and Drug Problems, Volume 9. New York: Plenum Press, 1986. pp. 279-314.

Sinclair, J.D.: Morphine suppresses alcohol drinking regardless of prior alcohol access duration. Pharmacology, Biochemistry and Behavior 2:409-412, 1974.

Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies.: National Household Survey on Drug Abuse Advance Report No. 18. Rockville, MD: Substance Abuse and Mental Health Services Administration, 1996. http://ncadi.samhsa.gov/ [Accessed Nov. 6, 1997].

Suzdak, P.D.; ~~Schwarz,~~ Schwartz, R.D.; Skolnick, P.; and Paul, S.M.: Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proceedings of the National Academy of Sciences 83:4071-4075, 1986.

Swift, R.M.: Effect of naltrexone on human alcohol consumption. Journal of Clinical Psychiatry 56(suppl. 7):24-29, 1995.

Swift, R.M.; Whelihan, W.; Kuznetsov, O.; Buongiorno, G.; and Hsuing, H.: Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry 151:1463-1467, 1994.

Thiagarajan, A.B.; Mefford, I.N.; and Eskay, R.L.: Single-dose ethanol administration activates the hypothalamic-pituitary axis: Exploration of the mechanism of action. Neuroendocrinology 50:427-432, 1989.

Ulm, R.R.; Volpicelli, J.R.; and Volpicelli, L.A.: Opiates and alcohol self-administration in animals. Journal of Clinical Psychiatry 56(suppl. 7):5-14, 1995.

Verebey, K.; De Pace, A.; Jukofsky, D.; Volabka, J.V.; and Mule, S.J.: Quantitative determination of 2-hydroxy-3-methoxy-6 beta-naltrexol (HMN), naltrexone, and 6 beta-naltrexol in human plasma, red blood cells, saliva, and urine by has liquid chromatography. Journal of Analytical Toxicology 4(1):33-37, 1980.

Verebey, K.; Volavka, J.; Mule, S.J.; and Resnick, R.B.: Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacology and Therapeutics 20: 315-328, 1976.

Volpicelli, J.R.: Medical Treatments for Alcohol Dependence. Speech delivered by satellite broadcast to Veterans' Affairs hospitals in the United States and reported by the Treatment Research Center, on November 30, 1995.

Volpicelli, J.R., and O'Brien, C.P.: Introduction: Opioid involvement in alcohol dependence. Journal of Clinical Psychiatry 56(suppl. 7):3-4, 1995.

Volpicelli, J.R.; Alterman, A.I.; Hayashida, M.; and O'Brien, C.P.: Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49:876-880, 1992.

Volpicelli, J.R.; Clay, K.L.; Watson, N.T.; and O'Brien, C.P.: Naltrexone in the treatment of alcoholism: Predicting response to naltrexone. Journal of Clinical Psychiatry 56(suppl. 7):39-44, 1995a.

Volpicelli, J.R.; Clay, K.L.; Watson, N.T.; and Volpicelli, L.A.: Naltrexone and the treatment of alcohol dependence. Alcohol Health and Research World 18:272-278, 1994.

Volpicelli, J.R.; Rhines, K.C.; Rhines, J.S.; Volpicelli, L.A.; and O'Brien, C.P.: Naltrexone and alcohol dependence: Role of subject compliance. Archives of General Psychiatry 54:737-743, 1997.

Volpicelli, J.R.; Ulm, R.R.; and Hopson, N.: Alcohol drinking in rats during and following morphine injections. Alcohol 8:289-292, 1991.

Volpicelli, J.R.; Volpicelli, L.A.; and O'Brien, C.P.: Medical management of alcohol dependence: Clinical use and limitations of naltrexone treatment. Alcohol and Alcoholism 30:789-798, 1995b.

Wikler, W.A.: Recent progress in research on the neurophysical basis of morphine addiction. American Journal of Psychiatry 105:328-338, 1948.

Wikler, W.A., and Pescor, F.T.: Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid drinking behavior and "relapse" in morphine addicted rats. Psychopharmacologia 10:255-284, 1967.

Wilde, M.I., and Wagstaff, A.J.: Acamprosate: A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53(6):1038-1053, 1997.

Wise, R.A.: Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Science 5:39-87, 1982.

Zink, R.W.; Rohrbach, K.; and Froehlich, J.C.: Naltrexone and fluoxetine act synergistically to decrease alcohol intake. Alcoholism: Clinical and Experimental Research 21(5):104A, 1997.

Table of Contents

Initiatives | Funding | Home

	U.S. Department of Health and Human Services
	Substance Abuse and Mental Health Services Administration
	Center for Mental Health Services
	Center for Substance Abuse Prevention
	Center for Substance Abuse Treatment

(800) 729-6686

TDD: (800) 487-4889

Español: (877) 767-8432

SAMHSA Home | Freedom of Information Act | Department of Health and Human Services | The White House | USA.gov

Naltrexone And Alcoholism Treatment Treatment Improvement Protocol (TIP) Series 28

Appendix A -- Bibliography

Naltrexone And Alcoholism Treatment
Treatment Improvement Protocol (TIP) Series 28